Trial of anti-malarials to prevent coronavirus resumes
The UK trial of hydroxychloroquine and chloroquine was put on hold after another study found hydroxychloroquine had no benefit as a treatment
A global trial designed to test whether two anti-malaria drugs can prevent infection with COVID-19 is to restart after being approved by British regulators.
The trial was paused pending review after another UK trial found hydroxychloroquine had no benefit as a treatment in patients already infected with the virus .
The trial is a randomised, placebo-controlled study of hydroxychloroquine and chloroquine, led by the Oxford University’s Mahidol Oxford Tropical Medicine Research Unit (MORU) in the Thai capital of Bangkok.
It aims to enrol 40,000 healthcare workers and other at-risk staff around the world.
